Jun Gong MDAssistant Professor, Department of Medicine, Division of Hematology and Oncology, Cedars-Sinai Medical Center, Los Angeles, California
Jun Gong, MD, is an Assistant Professor in the Department of Medicine, Division of Hematology and Oncology at Cedars-Sinai Medical Center. As a medical oncologist, his primary clinical interests are in gastrointestinal (GI), hepatobiliary, and genitourinary (GU) cancers with a multidisciplinary focus of care along with colleagues from surgery, gastroenterology, radiation oncology, radiology, and urology. Dr. Gong is focused on translational and clinical cancer research with interests in early therapeutic trials (immunotherapy, targeted therapies, biologics, and other systemic therapies) and biomarker development to improve patient outcomes in GI and GU cancers.
Consultant or Advisory Role – EMD Serono, Elsevier, Exelixis, QED Therapeutics, Natera, Basilea, HalioDx, Eisai, Janssen, Astellas, Amgen, Pfizer, Seagen, and Bayer.
Recent Contributions to PracticeUpdate:
- How Involvement in Research Can Help Develop Your Career
- Frontline ICI-Based Combination Therapy in Patients With Metastatic RCC With Poor Performance Status
- Perioperative Morbidity Associated With Metastasectomy in Patients With Renal Cell Carcinoma
- 2022 Top Story in Renal Cell Carcinoma: Triplet Combination Therapy for Advanced RCC
- Safety of Concurrent Radiotherapy and Cabozantinib Use for Treating Patients With Metastatic RCC
- Surgical Management and Oncologic Outcomes for Local Retroperitoneal Recurrence of RCC After Radical Nephrectomy
- Efficacy and Safety of Nivolumab Plus Ipilimumab in the Second-Line Setting in Advanced RCC
- Safety of Concurrent Use of Cabozantinib With Direct Oral Anticoagulants in Patients With mRCC
- Nivolumab Plus Ipilimumab Plus Cabozantinib Triplet Combination for Patients With Previously Untreated Advanced RCC
- PFS After Second-Line Therapy in Patients With Metastatic ccRCC Treated With First-Line Immunotherapy Combinations